Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: The LAPTEM trial

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2985-2989

  de Azambuja, E ^a   Zardavas, D ^a   Lemort, M ^a   Rossari, J ^b   Moulin, C ^c   Buttice, A ^a   D'Hondt, V ^a   Lebrun, F ^a   Lalami, Y ^a   Cardoso, F ^d   Sotiriou, C ^a   Gil, T ^a   Devriendt, D ^a   Paesmans, M ^a   Piccart Gebhart, M ^a   Awada, A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b HOSPITAL MOINHOS DE VENTO   (Brazil)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Champalimaud Cancer Center   (Portugal)

Author keywords

Brain metastases; Breast cancer; HER2; Lapatinib; Temozolomide

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOLINIUM; LAPATINIB; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BLEEDING; BRAIN METASTASIS; BREAST METASTASIS; CHOLESTASIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPONATREMIA; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MORTALITY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEIZURE; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA;

BRAIN METASTASES; BREAST CANCER; HER2; LAPATINIB; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84888804829     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt359     Document Type: Article

References (24)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-182.
2. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55(7-9): 685-696.
3. Arteaga CL, Sliwkowski MX, Osborne CK et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9(1): 16-32.
4. Nussbaum ES, Djalilian HR, Cho KH et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996; 78(8): 1781-1788.
5. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17(6): 935-944.
6. Pinder MC, Chang H, Broglio KR et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases. J Clin Oncol 2007; 25: 36s (suppl 18; abstr 1018).
7. Stemmler H-J, Schmitt M, Willems A et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18(1): 23-28.
8. Steeg PS. Brain Metastasis: a Unique Microenvironment and a Sanctuary from Chemotherapy. AACR 101st Annual Meeting. Educational Book 2010, p.91-93.
9. Taskar KS, Rudraraju V, Mittapalli RK et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012; 29(3): 770-781.
10. Nahta R, Yuan LXH, Du Y et al. Lapatinib induces apoptosis in trastuzumabresistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6(2): 667-674.
11. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26(12): 1993-1999.
12. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-2743.
13. Lin NU, Dieras V, Paul D et al. EGF105084 Study Group. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 25 (18S) (June 20 Supplement), 2007: 1012.
14. Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs. 2011; 20(7): 881-895.
15. Lin NU. CNS metastases in breast cancer. J Clin Oncol 2004; 22(17):3608-3617.
16. Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107(6): 1348-1354.
17. Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22(3): 625-630.
18. Bachelot T, Romieu G, Campone M et al. LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). 2011 ASCO Annual Meeting J Clin Oncol 2011; 9 (suppl; abstr 509).
19. Platta CS, Khuntia D, Mehta MP et al. Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 2010; 33(4): 398-407.
20. Pivot X, Semiglazov V, Zurawski B et al. CEREBEL (EGF111438): An open label randomized Phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC). ESMO 2012 Congress, Ann Oncol 2012; 23 (suppl 9; LBA LBA11).
21. Addeo R, Caraglia M. The oral tyrosine kinase inhibitors lapatinib and sunitinib:new opportunities for the treatment of brain metastases from breast cancer? Expert Rev Anticancer Ther 2011; 11(2): 139-142.
22. Addeo R, Sperlongano P, Montella L et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol. [Internet]. 2012. http://www.ncbi.nlm.nih.gov/pubmed/22890892 (21 September 2012, date last accessed).
23. Rubin P, Gash DM, Hansen JT et al. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol 1994; 31(1): 51-60.
24. Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15(4): 1452-1459.